Kazumi Nishino

10PUBLICATIONS
101CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 25, 2025
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.

Kazumi Nishino, Takashi Seto, Makoto Nishio

|Sep 13, 2025
Tumor Cell Proportion Assessment in Advanced Non-Squamous Non-Small Cell Lung Cancer Tissue Samples in Real-World Settings in Japan: The ASTRAL Study.

Kanako C Hatanaka, Kazumi Nishino, Tomoyuki Yokose

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

|Jan 24, 2025
Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.

Hironari Tamiya, Kazumi Nishino, Yuji Kato

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Jun 06, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

D Ross Camidge, Jair Bar, Hidehito Horinouchi

Pageof 2

Frequent Collaborators

3 joint publications

Naoki Furuya

2 joint publications

Yasuhiro Goto

2 joint publications

Hidetoshi Hayashi

2 joint publications

Satoru Miura